This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Voog, E. Articles by Salles, G. Search for Related Content PubMed PubMed Citation Articles by Voog, E. Articles by Salles, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE DOXORUBICIN Medline Plus Health Information Lymphoma

Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System

From the Service d’Hématologie and Laboratoire d’Immunologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite; and Jeune Equipe (Pathologie des Cellules Lymphoïdes), Université Claude Bernard, Lyon, France.

Address reprint requests to G. Salles, Service d’Hématologie, Centre Hospitalier Lyon-Sud, 69495 Pierre-Benite Cedex, France; email gilles.salles{at}chu-lyon.fr

PURPOSE: To analyze factors that predict the occurrence of chemotherapy-induced myelosuppression and, in particular, the role of the tumor necrosis factor (TNF) ligand-receptor system in lymphoma patients at the beginning of their treatment.

PATIENTS AND METHODS: We investigated the predictive factors for myelosuppression after the first course of chemotherapy in a cohort of 101 consecutive, previously untreated lymphoma patients receiving regimens that include doxorubicin and cyclophosphamide. Plasma samples were tested at baseline by enzyme-linked immunosorbent assay for TNF and its soluble receptors. Univariate and multivariate analyses were performed with a forward regression procedure that included all of the parameters that were found to be significant in the univariate analysis. The dose of chemotherapy and the prophylactic treatment with granulocyte colony-stimulating factor were deliberately included in this model.

RESULTS: Sixty-seven patients experienced World Health Organization (WHO) grade 4 neutropenia, and 37 patients experienced febrile neutropenia, which was responsible for WHO grade 2 through 4 infections in 23 patients. In multiparametric regression analysis, the occurrence of grade 4 neutropenia was associated with high doses of cyclophosphamide (odds ratio [OR], 19.8; P = .008) and high levels of soluble p75-R-TNF (OR, 8.52; P = .001). The duration of grade 4 neutropenia for more than 5 days was associated with the lack of hematopoietic growth factor administration (OR, 6.76; P = .004) and high levels of soluble p75-R-TNF (OR, 5.84; P = .0023). The occurrence of febrile neutropenia was associated with high doses of cyclophosphamide (OR, 4.7; P = .007), altered performance status (OR, 18.8; P < .0001) and high levels of soluble p75-R-TNF (OR, 3.49; P = .029).

CONCLUSION: This study indicates that in addition to the dose of chemotherapy and the administration of hematopoietic growth factors, poor performance status and high p75-R-TNF levels can predict the occurrence of chemotherapy-induced myelosuppression in lymphoma patients. This model may help in selecting patients for prophylactic growth factor administration.

This article has been cited by other articles:

				M. Ziepert, R. Schmits, L. Trumper, M. Pfreundschuh, M. Loeffler, and On behalf of the German High-Grade Non-Hodgkin's L Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma Ann. Onc., April 1, 2008; 19(4): 752 - 762. [Abstract] [Full Text] [PDF]

				G. H. Lyman, C. H. Lyman, O. Agboola, and for the Anc Study Group Risk Models for Predicting Chemotherapy-Induced Neutropenia Oncologist, June 1, 2005; 10(6): 427 - 437. [Abstract] [Full Text] [PDF]

				S. M. Horwitz, R. S. Negrin, K. G. Blume, S. Breslin, M. J. Stuart, K. E. Stockerl-Goldstein, L. J. Johnston, R. M. Wong, J. A. Shizuru, and S. J. Horning Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood, February 1, 2004; 103(3): 777 - 783. [Abstract] [Full Text] [PDF]

				J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood, January 1, 2003; 101(1): 6 - 14. [Abstract] [Full Text] [PDF]

				G. A. Wiseman, L. I. Gordon, P. S. Multani, T. E. Witzig, S. Spies, N. L. Bartlett, R. J. Schilder, J. L. Murray, M. Saleh, R. S. Allen, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial Blood, May 29, 2002; 99(12): 4336 - 4342. [Abstract] [Full Text] [PDF]

				M. Wilson-Royalty, G. Lawless, C. Palmer, and R. Brown Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 141 - 147. [Abstract] [PDF]